SCHEMBL20965430

SCHEMBL20965430

Cc1cc(CSc2ncccc2C(=O)N2CCN(c3ncc(Br)cn3)CC2)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
HTT P42858 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 2/20 0.45
ALDH1A1 P00352 6/20 0.43
TSHR P16473 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 6/20 0.42
MCL1 Q07820 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
TP53 P04637 2/20 0.40
HPGD P15428 2/20 0.40
CYP3A4 P08684 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20965301 0.93 PKM (0.53) MAPTHTTTDP1SMN1; SMN2PKM
SCHEMBL20965325 0.85 MAPT (0.54) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL20964635 0.84 ALDH1A1 (0.63) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL20964674 0.83 SMN1; SMN2 (0.51) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL20964624 0.83 GAA (0.47) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL20964566 0.82 ALDH1A1 (0.48) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL20964538 0.82 SMN1; SMN2 (0.51) MAPTHTTTDP1SMN1; SMN2PKM
SCHEMBL20964663 0.81 ALDH1A1 (0.47) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL19748152 0.81 KDM4E (0.68) MAPTHTTTDP1SMN1; SMN2ALDH1A1
SCHEMBL20965431 0.79 ALDH1A1 (0.47) MAPTHTTTDP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 MAPT 1626/4885HTT 2154/4885TDP1 3109/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 MAPT 4673/4885HTT 2335/4885TDP1 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.